ELANE Knockout PaTu 8988t Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population in which the ELANE gene has been disrupted to generate a heterogeneous loss-of-function pool. This product provides a physiologically relevant human pancreatic cancer model for investigating the roles of neutrophil elastase in tumor biology, without relying on clonal isolation.
The host cell line, PaTu 8988t, is a human pancreatic ductal adenocarcinoma cell line originally derived from a liver metastasis of a pancreatic adenocarcinoma patient. This cell line serves as a widely used in vitro model for pancreatic cancer research, retaining key features of tumor cell behavior, including invasive potential and altered signaling networks.
Neutrophil elastase, encoded by ELANE, is a serine protease that degrades extracellular matrix components such as elastin and collagen IV, modulates inflammatory responses, and influences apoptotic pathways. Its activity is regulated by upstream factors including the transcription factors C/EBPA and SPI1 (PU.1) and cytokines such as G-CSF, TNF, and IL-1??. Downstream, ELANE targets structural proteins and signaling molecules like MMP9, IL-8 receptor, TNF receptor, caspase-3, and EGFR, while being inhibited by interacting factors SERPINA1 (alpha-1-antitrypsin), SLPI, alpha-2-macroglobulin, and thrombomodulin. In the polyclonal knockout pool, disruption of ELANE eliminates elastase activity, thereby impairing extracellular matrix degradation and altering signaling pathways such as EGFR activation and caspase-3-mediated apoptosis.
In the context of PaTu 8988t pancreatic cancer cells, loss of ELANE function provides a valuable tool for dissecting the protease??s contributions to tumor invasion and the modulation of the tumor microenvironment. Neutrophil elastase has been implicated in promoting cancer cell migration through ECM remodeling and in shaping inflammatory signaling that supports tumor progression. The polyclonal knockout population therefore enables researchers to assess how the absence of ELANE affects key cancer hallmarks, including invasive capacity, apoptotic responses, and sensitivity to chemotherapeutic agents.
This knockout model is well-suited for a range of applications, including pancreatic cancer invasion and metastasis studies, ELANE inhibitor screening, tumor microenvironment investigations, and drug sensitivity testing. Representative experimental approaches include western blotting to confirm ELANE ablation, elastase activity assays to verify functional loss, cell migration and invasion assays (e.g., Boyden chamber), gelatin zymography for MMP activity, apoptosis assays detecting caspase-3 activation, xenograft tumor growth studies, cytokine profiling, and RNA-seq for transcriptomic analysis. For further information or to discuss your specific experimental needs, please contact Ascent Research.
